Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Chembio Diagnostics Inc (CEMI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Chembio's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Chembio historical data, for real-time data please try another search
0.455 +0.000    +0.00%
27/04 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.430 / 0.449
  • Day's Range: 0.447 - 0.455
Chembio 0.455 +0.000 +0.00%

NASDAQ:CEMI Financials

 
A brief overview of the NASDAQ:CEMI financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Chembio over time.

Chembio Diagnostics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 49.52 million compared to USD 47.82 million a year ago. Net loss was USD 23.29 million compared to USD 33.9 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 1.4 a year ago. Diluted loss per share from continuing operations was USD 0.72 compared to USD 1.4 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

CEMI Income Statement

Gross margin TTM -
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Revenue 10.34 11.2 9.16 18.82
Gross Profit 3.23 -0.33 -0.968 1.94
Operating Income -3.3 -5.88 -6.22 -5.01
Net Income -0.855 -6.7 -6.95 -8.79

CEMI Balance Sheet

Quick Ratio MRQ -
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Assets 62.61 62.18 56.06 62.89
Total Liabilities 44.81 44.39 36.15 36.36
Total Equity 17.8 17.79 19.9 26.54

CEMI Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -7.20%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -2.83 -5.06 -0.433 -4.37
Cash From Investing Activities 0.029 -0.345 -0.849 -0.287
Cash From Financing Activities -0.164 3.61 -0.019 -0.055
Net Change in Cash -2.88 -1.78 -1.56 -4.37
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CEMI Comments

Write your thoughts about Chembio Diagnostics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Neteli Neteli
Neteli Neteli Dec 30, 2021 6:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Chembio Diagnostics Inc - on December 21, FDA Notified Co That It Was Declining to Review Co's Application for Eua for Dpp Respiratory Antigen Panel. Chembio -fda Notice Said Co Will Need to Collect Influenza a & Influenza B Samples, Submit New Eua Application for Dpp Respiratory Antigen Panel.
Patricia Barros
Patricia Barros Dec 28, 2021 5:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any news?
Faster Hamed
Faster Hamed Nov 29, 2021 9:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Chembio Diagnostics (CEMI) gains 9.5% premarket after receiving South Africa Health Products Regulatory Authority ((SAHPRA)) approval for the DPP SARS-CoV-2 Antigen test,...
Faster Hamed
Faster Hamed Nov 26, 2021 8:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
up up
Faster Hamed
Faster Hamed Nov 15, 2021 9:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
HAUPPAUGE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the delivery schedule for shipments of DPP SARS-COV-2 Antigen Tests under its July 2021 purchase order from Bio Manguinhos has been extended into March 2021. As the result of a portion of the shipments now being deliverable after year end, Chembio believes it now has the opportunity to fulfill all of the $28.3 million order. Chembio's delivery of tests covered by the purchase order, however, continues to be negatively affected by limitations of Chembio's supply chain, staffing, and liquidity, and other matters outside Chembio's control.
Faster Hamed
Faster Hamed Nov 05, 2021 12:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
But I expect a rapid rise in the near future... I expect to sign an agreement to manufacture Covid devices
Faster Hamed
Faster Hamed Nov 05, 2021 12:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bad report
World Traveler
World Traveler Nov 03, 2021 1:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2 Major orders in this last Quarter Why is this stock not going up? what am i missing thats not in the news?
Tariq AlZadjali
Tariq AlZadjali Sep 28, 2021 12:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2.59 good to buy in my opinion
Faster Hamed
Faster Hamed Sep 17, 2021 11:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hm hm hm
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email